C
Chiara Mandoj
Publications - 31
Citations - 552
Chiara Mandoj is an academic researcher. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 8, co-authored 25 publications receiving 233 citations.
Papers
More filters
Journal ArticleDOI
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.
Raul Pellini,Aldo Venuti,Fulvia Pimpinelli,Elva Abril,Giovanni Blandino,Flaminia Campo,Laura Conti,Armando De Virgilio,Federico De Marco,Enea Gino Di Domenico,Ornella Di Bella,Simona di Martino,Fabrizio Ensoli,Diana Giannarelli,Chiara Mandoj,Valentina Manciocco,Paolo Marchesi,Francesco Mazzola,Silvia Moretto,Gerardo Petruzzi,Fabrizio Petrone,Barbara Pichi,Martina Pontone,Jacopo Zocchi,Antonello Vidiri,Branka Vujovic,Giulia Piaggio,Aldo Morrone,Gennaro Ciliberto +28 more
TL;DR: In this paper, the antibody titre changes in correlation with age, gender, BMI and hypertension were analyzed in a group of 248 healthcare workers after the second dose of BNT162b2 vaccine.
Journal ArticleDOI
PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience
Roberta Merola,Luigi Tomao,Anna Antenucci,Isabella Sperduti,Steno Sentinelli,Serena Masi,Chiara Mandoj,Giulia Orlandi,Rocco Papalia,Salvatore Guaglianone,Manuela Costantini,Giuseppe Cusumano,Giovanni Cigliana,Paolo Ascenzi,Michele Gallucci,Laura Conti +15 more
TL;DR: The PCA3 test showed the best diagnostic performance when compared to tPSA and f/tPSA, facilitating the selection of high-risk patients that may benefit from the execution of a saturation prostatic biopsy and showed a prognostic value, as higherPCA3 score values are associated to a greater tumor aggressiveness.
Posted ContentDOI
Obesity may hamper SARS-CoV-2 vaccine immunogenicity
Raul Pellini,Aldo Venuti,Fulvia Pimpinelli,Elva Abril,Giovanni Blandino,Flaminia Campo,Laura Conti,Armando De Virgilio,Federico De Marco,Enea Gino Di Domenico,Ornella Di Bella,Simona di Martino,Fabrizio Ensoli,Diana Giannarelli,Chiara Mandoj,Valentina Manciocco,Paolo Marchesi,Francesco Mazzola,Silvia Moretto,Gerardo Petruzzi,Fabrizio Petrone,Barbara Pichi,Martina Pontone,Jacopo Zocchi,Antonello Vidiri,Branka Vujovic,Giulia Piaggio,Aldo Morrone,Gennaro Ciliberto +28 more
TL;DR: In this paper, the antibody titre changes in correlation with age, gender and BMI after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCW) and showed that females, lean and young people have an increased capacity to mount humoral immune responses compared to males, overweight and the older population.
Journal ArticleDOI
Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution.
Vincenzo Di Noia,Fulvia Pimpinelli,Davide Renna,Vittoria Barberi,Maria Teresa Maccallini,Ludovica Gariazzo,Martina Pontone,Alessandro Monti,Flaminia Campo,Emanuela Taraborelli,Maria Di Santo,Fabrizio Petrone,Chiara Mandoj,Virginia Ferraresi,Gianluigi Ferretti,Paolo Carlini,Ornella Di Bella,Laura Conti,Antonia La Malfa,Raul Pellini,Domenico Bracco,Diana Giannarelli,Aldo Morrone,Francesco Cognetti +23 more
TL;DR: In this article, the authors assessed the immunogenicity and safety of the BNT162b2 vaccine in a large cohort of patients with cancer (CP) in a prospective cohort study, which included 816 CP afferent to our Institution and eligible to the vaccination.
Journal ArticleDOI
Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI.
Raul Pellini,Aldo Venuti,Fulvia Pimpinelli,Elva Abril,Giovanni Blandino,Flaminia Campo,Laura Conti,Armando De Virgilio,Federico De Marco,Enea Gino Di Domenico,Ornella Di Bella,Simona di Martino,Fabrizio Ensoli,Diana Giannarelli,Chiara Mandoj,Valentina Manciocco,Paolo Marchesi,Francesco Mazzola,Silvia Moretto,Gerardo Petruzzi,Fabrizio Petrone,Barbara Pichi,Martina Pontone,Jacopo Zocchi,Antonello Vidiri,Branka Vujovic,Giulia Piaggio,Aldo Morrone,Gennaro Ciliberto +28 more
TL;DR: In this article, the first dose of the BNT162b2 vaccine activated immune responses in 98% of the participants and was associated with age, gender and body mass index (BMI).